Duchenne muscular dystrophy: from gene to gene-ius therapies Authors: Antoine Muchir, Antonio Musaro, Jeffrey Chamberlain Published: 2026 ABSTRACT AbstractDuchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder caused by mutations in the dystrophin gene that result in the absence of functional dystrophin, leading to progressive muscle degeneration, loss of ambulation, respiratory failure, cardiomyopathy, and premature mortality. Despite advances in multidisciplinary supportive care, DMD remains an incurable disease associated with substantial physical, psychosocial, and economic burdens. The monogenic nature of DMD and its well-defined molecular pathogenesis have made it a prime target for the development of precision therapies aimed at restoring dystrophin expression or modifying disease progression. This review provides an overview of the genetic and molecular mechanisms underlying DMD, summarizes its clinical manifestations and natural history, and discusses current standards of care. It further examines recent advances in disease-modifying therapeutic strategies, including exon-skipping antisense oligonucleotides, nonsense mutation readthrough agents, adeno-associated virus (AAV)-mediated micro-dystrophin gene replacement, and emerging genome-editing technologies such as CRISPR/Cas9. The review also highlights the limitations of existing treatments, including mutation specificity, variable efficacy, immune-related challenges, and uncertainties regarding long-term durability and safety. Finally, it considers future directions in therapeutic development, emphasizing the need for combination approaches, improved delivery systems, and next-generation gene-editing platforms to achieve more effective and lasting clinical outcomes. Collectively, these advances represent a paradigm shift in DMD management and offer renewed hope for improving survival and quality of life for affected individuals.Keywords: Duchenne muscular dystrophy, Pathogenic mechanisms of DMD, Therapeutic strategies Introduction Duchenne muscular dystrophy (DMD) is a severe, progressive X-linked neuromuscular disorder characterized by early-onset muscle degeneration and weakness, ultimately leading to loss of ambulation, respiratory insufficiency, cardiomyopathy, and premature death. First described by Guillaume Duchenne in the 19th century, DMD remains one of the most common inherited muscle diseases in childhood, with a global incidence estimated at approximately 1 in 3,500–5,000 live male births [1, 2]. Although primarily affecting boys, rare cases in females can occur due to skewed X-inactivation or chromosomal abnormalities. The molecular basis of DMD lies in mutations of the DMD gene, one of the largest genes in the human genome. This gene encodes dystrophin, a key cytoskeletal protein that connects the intracellular actin cytoskeleton to the extracellular matrix via the dystrophin-associated protein complex. This structural linkage is essential for maintaining sarcolemmal integrity during muscle contraction [2]. Mutations ‒ including large deletions (~ 60–70%), duplications (~ 5–10%), and small sequence variants such as nonsense or splice-site mutations ‒ disrupt dystrophin expression, rendering muscle fibers highly susceptible to mechanical damage [3]. The absence of functional dystrophin initiates a cascade of degeneration, inflammation, and eventual replacement of muscle tissue with fat and fibrotic deposits. Clinically, DMD presents in early childhood with delayed motor milestones, proximal muscle weakness, and characteristic features such as Gowers’ sign. Disease progression is relentless, with most patients losing independent ambulation by their early teens [4]. Cardiac involvement, particularly dilated cardiomyopathy, and progressive respiratory decline are major contributors to morbidity and mortality. Despite improvements in multidisciplinary care, including corticosteroid therapy, ventilatory support, and cardiac management, life expectancy typically extends only into the third or fourth decade [5]. The disease imposes a substantial burden not only on patients but also on caregivers and healthcare systems, encompassing physical disability, psychosocial stress, and significant economic costs. The well-characterized genetic etiology and monogenic nature of DMD make it an attractive candidate for targeted therapeutic development. Over recent decades, significant advances have been made in approaches aimed at restoring dystrophin expression or mitigating downstream pathology. These include exon-skipping therapies using antisense oligonucleotides, nonsense mutation readthrough strategies, micro-dystrophin gene replacement via viral vectors, and emerging genome editing technologies such as CRISPR/Cas9 [6, 7]. While some therapies have achieved conditional approval, their clinical benefits remain partial, highlighting the urgent need for more effective and durable treatments. Continued research efforts are therefore critical to address the unmet medical need and to transform DMD from a fatal disease into a manageable condition. Molecular and cellular pathophysiology Role of dystrophin in muscle Dystrophin is a key structural and signaling protein essential for maintaining skeletal and cardiac muscle integrity. Located at the inner surface of the sarcolemma, dystrophin provides a mechanical link between the intracellular cytoskeleton and the extracellular matrix, thereby protecting muscle fibers from contraction-induced damage. In DMD, the absence of functional dystrophin destabilizes the muscle membrane, leading to increased susceptibility to injury, calcium influx, and progressive muscle degeneration [8, 9]. Structurally, dystrophin is a large rod-shaped protein and composed of several distinct domains that contribute to its function. The N-terminal domain binds to F-actin in the cytoskeleton, while the central rod domain ‒ consisting of spectrin-like repeats ‒ provides flexibility and elasticity. The cysteine-rich domain and C-terminal region mediate interactions with membrane-associated proteins, anchoring dystrophin to a larger multiprotein assembly at the sarcolemma [10]. This modular structure allows dystrophin to act as a molecular shock absorber, distributing mechanical stress during cycles of muscle contraction and relaxation. Dystrophin functions as the central component of the dystrophin-associated protein complex (DAPC), a critical multiprotein network that spans the sarcolemma. The DAPC includes integral membrane proteins such as dystroglycans and sarcoglycans, as well as cytoplasmic and extracellular components that collectively stabilize the muscle fiber membrane and facilitate signal transduction [11]. Dystrophin primarily functions as a structural scaffold that stabilizes the sarcolemma by linking the intracellular actin cytoskeleton to the extracellular matrix through the dystrophin-associated protein complex (DAPC). Through its interaction with β-dystroglycan, dystrophin connects to α-dystroglycan, which in turn binds extracellular matrix proteins such as laminin. This continuous linkage between the cytoskeleton and the extracellular environment is essential for maintaining muscle fiber integrity and protecting the sarcolemma from contraction-induced damage. Beyond its mechanical role, the DAPC serves as a platform for the localization and organization of signaling proteins, including neuronal nitric oxide synthase (nNOS), at the sarcolemma. Consequently, dystrophin deficiency, as observed in DMD, not only compromises membrane stability but also indirectly disrupts multiple signaling pathways, including nitric oxide (NO)/cGMP signaling, calcium homeostasis, inflammatory NF-κB signaling, TGF-β-mediated fibrosis, oxidative stress responses, and muscle regenerative pathways [12, 13]. These combined structural and signaling defects contribute to the progressive muscle degeneration characteristic of DMD. A detailed understanding of dystrophin structure and its interactions within the DAPC has therefore been fundamental in guiding the development of targeted therapeutic strategies aimed at restoring or functionally replacing dystrophin. Beyond the well-established structural defects in myofibers, DMD is increasingly recognized as a disease of dysfunctional muscle stem cells (satellite cells), whose intrinsic defects substantially contribute to disease progression. In healthy muscle, satellite cells maintain regenerative capacity through a tightly regulated balance between self-renewal and differentiation, supported by dystrophin-mediated establishment of cell polarity and asymmetric cell division [14–16]. In dystrophic muscle, the absence of dystrophin disrupts polarity signaling, leading to defective asymmetric divisions, reduced generation of myogenic progenitors, abnormal mitotic events, accelerated differentiation, mitochondrial dysfunction, oxidative stress, cellular senescence, and altered epigenetic regulation [17, 18]. These cell-autonomous defects impair the regenerative potential of satellite cells despite their increased numbers, resulting in an inability to adequately repair repeated cycles of muscle damage and ultimately promoting fibrosis, chronic inflammation, and progressive muscle wasting [19]. Together, these findings support the concept that successful treatment of DMD will require not only protection of dystrophic myofibers but also restoration of the regenerative competence of endogenous satellite cells. Mechanisms of muscle degeneration The absence of dystrophin in DMD leads to profound alterations in muscle cell homeostasis, initiating a cascade of pathological events that drive disease progression (Fig. 1). One of the earliest and most critical consequences is membrane instability. Without dystrophin and its associated protein complex, the sarcolemma becomes fragile and susceptible to contraction-induced damage, resulting in microtears that compromise cellular integrity [9, 20]. This mechanical vulnerability facilitates the uncontrolled exchange of ions and molecules between the intracellular and extracellular environments. A key downstream effect of membrane disruption is calcium dysregulation. Increased sarcolemmal permeability allows excessive influx of Ca2+ into muscle fibers, overwhelming intracellular buffering systems. Elevated cytosolic calcium activates proteases such as calpains and disrupts normal cellular processes, contributing to myofiber necrosis [13]. In parallel, abnormal calcium handling by the sarcoplasmic reticulum further exacerbates this imbalance, amplifying muscle damage over time. Mitochondrial dysfunction is another central feature of DMD pathophysiology. Excess intracellular calcium accumulates within mitochondria, impairing oxidative phosphorylation and promoting the opening of the mitochondrial permeability transition pore. This leads to reduced ATP production, increased generation of reactive oxygen species (ROS), and activation of cell death pathways [21]. Energetic deficits and mitochondrial damage further compromise muscle fiber survival and regeneration. Oxidative stress plays a critical role in amplifying muscle injury. Elevated ROS levels, derived from dysfunctional mitochondria and inflammatory cells, cause damage to lipids, proteins, and DNA. In healthy muscle, antioxidant systems mitigate these effects; however, in DMD, this balance is disrupted, resulting in cumulative oxidative damage that accelerates disease progression [22]. Chronic inflammation is a hallmark of DMD and contributes significantly to disease pathology. Muscle fiber damage triggers infiltration of immune cells, including macrophages and neutrophils, which release pro-inflammatory cytokines and additional ROS. While initially part of a repair response, persistent inflammation leads to a maladaptive cycle of degeneration and impaired regeneration. Over time, this environment promotes fibrosis, characterized by excessive deposition of extracellular matrix components such as collagen, ultimately replacing functional muscle tissue and reducing contractile capacity [23]. Together, membrane instability, calcium overload, mitochondrial dysfunction, oxidative stress, and chronic inflammation form an interconnected network of pathological mechanisms. These processes not only drive progressive muscle degeneration but also represent important therapeutic targets aimed at slowing or halting disease progression. Overview of Duchenne muscular dystrophy (DMD): from disease mechanisms to current and emerging therapeutic strategies. The figure summarizes the genetic and molecular basis of DMD, its clinical manifestations and natural history, current standards of care, and disease-modifying therapies, including exon-skipping antisense oligonucleotides, nonsense mutation readthrough agents, adeno-associated virus (AAV)-mediated micro-dystrophin gene replacement, and CRISPR/Cas9-based genome editing. It also highlights the major limitations of existing therapies, such as mutation specificity, variable efficacy, immune-related challenges, and uncertainties regarding long-term safety and durability, as well as future directions focused on combination therapies, improved delivery systems, and next-generation gene-editing approaches Experimental models Animal models Several mouse models have been generated to characterize the pathogenesis of DMD and to test the different therapeutic strategies. The mdx mouse (C57BL/10ScSn-Dmdmdx/J), although it does not fully reproduce the severity of human DMD, largely because of its strong regenerative capacity, represents the most widely used and extensively characterized murine model of DMD [24]. This model carries a nonsense mutation in exon 23 of DMD gene, resulting in the absence of full-length dystrophin. The mdx mice undergo extensive myofiber necrosis, elevated serum biomarkers, including creatine kinase levels, and increased susceptibility to fatigue at approximately 3–4 weeks of age, which represents a well-described acute phase of muscle degeneration [24]. Importantly, many of these biomarkers were similarly elevated in patients with DMD. This acute degenerative stage therefore recapitulates key early pathological events observed in human disease and provides a reproducible window for mechanistic and interventional studies. By adulthood (~ 6 months of age), the mdx mouse model displays a comparatively stable phase, where even diaphragm pathology, which represent the most compromised muscle in both human patients and mdx mice, becomes less severe, exhibiting significantly reduced necrosis compared with 4-week-old animals [25]. However, this reduction in ongoing muscle turnover is still accompanied by slow and continual loss of muscle mass, and two-year-old mdx show significant weakness and fibrosis [26–28]. Among potential factors, a diminished chronic inflammatory response contributes to the relatively milder dystrophic phenotype observed in adult mdx muscle. More severe dystrophic manifestations, including progressive muscle wasting, scoliosis, and cardiac dysfunction, generally do not develop until mdx mice reach 15 months of age or older [26, 29–31]. Over the years, several additional mdx-like strains have been generated, including mdx2cv, mdx4cv, and mdx5cv, each carrying distinct point mutations within the dystrophin gene. These models generally exhibit a more severe dystrophic phenotype than the original mdx mouse, in part because they display markedly fewer revertant fibers, a phenomenon in which dystrophin expression is spontaneously restored in a subset of muscle fibers through naturally occurring exon skipping or secondary compensatory events [32, 33]. The reduced frequency of revertant fibers in these strains minimizes endogenous dystrophin restoration and provides a more consistent background for evaluating therapeutic interventions, particularly those aimed at dystrophin rescue. In addition to these allelic variants, several modified and alternative models have been developed, including telomerase-deficient mdx/mTR mice [34], which exhibit impaired satellite cell function and reduced regenerative capacity, as well as more severe strains such as mdx/Utrn-/- [35], DBA/2J-mdx [36, 37], and mdx4cv/mTRG2 [38–40], which display increased fibrosis, cardiomyopathy, and disease progression. Additional insight has been gained from double-knockout models targeting complementary pathways involved in muscle integrity and regeneration. The mdx/Itgα7−/− mouse, which lacks the laminin-binding integrin α7 (Itgα7) complex develops severe muscle wasting and early lethality due to respiratory failure [41]. Likewise, the mdx/Myod1-/-, lacking the model myogenic regulator MyoD1, leads to impaired regeneration, reduced muscle mass, kyphosis and premature death [42, 43]. Metabolic and glycosylation pathways also modulate disease severity, as illustrated by the mdx/Cmah-/- mouse which combines the mdx mutation (a nonsense mutation in exon 23 of the Dmd gene) with deletion of the Cmah (cytidine monophosphate-N-acetylneuraminic acid hydroxylase) gene. Loss of Cmah “humanizes” the mouse glycome by mimicking the human condition, in which the CMAH enzyme is naturally inactive, preventing the synthesis of N-glycolylneuraminic acid (Neu5Gc) [38]. This mouse model exhibits increased fibrosis, early cardiac abnormalities and reduced lifespan [38, 44]. Collectively, these models highlight how perturbations beyond dystrophin deficiency, affecting extracellular matrix interactions, regenerative capacity and systemic metabolism, can markedly exacerbate dystrophic pathology. However, several aspects, including the disruption of structural or myogenic pathways which are not implicated in the human condition, must be considered when evaluating the animal models for use in the preclinical testing of potential new treatment options. Larger animal models, particularly dystrophic dogs, more closely mirror the physiological and clinical manifestations of DMD. Nevertheless, the high costs of management, ethical considerations, and low experimental throughput significantly limit their use. The development of genome-editing technologies has enabled the generation of DMD models in intermediate species, including rabbits, pigs, non-human primates, and notably rats, thereby creating a more tractable bridge between mice and large mammals. Among these, rat models have emerged as an especially valuable platform (reviewed [45]). Compared with mdx mice, dystrophin-deficient rats display a more severe and progressive phenotype, characterized by pronounced muscle wasting, early cardiac and diaphragmatic involvement, and shortened lifespan. These features more closely resemble the human condition while preserving the practical advantages of rodent systems. Since the first descriptions of dystrophic rat models in 2014, a broad range of lines has been generated to reflect the mutational diversity observed in patients, including exon-targeted knockouts (such as exon 23, exons 22–26, and exon 52 deletions) as well as models carrying clinically relevant duplications. Despite these advances, and notwithstanding its limitations, the mdx mouse remains the most widely used model due to its accessibility, reproducibility, and extensive characterization. In vitro models Animal models remain indispensable for investigating systemic disease features and evaluating therapeutic efficacy in vivo. Complementing these approaches, in vitro systems provide relevant platforms that enable the controlled investigation of disease mechanisms, cellular responses, and therapeutic interventions under well-defined experimental conditions. However, traditional in vitro models, which are largely based on two-dimensional (2D) cultures of immortalized or primary myoblasts, fail to capture the structural and functional complexity of mature skeletal muscle tissue, as they lack the mechanical cues and multicellular interactions that are essential for muscle homeostasis and disease modeling. To overcome this limitation, several in vitro systems have been developed. Among these, three-dimensional (3D) tissue engineering and human induced pluripotent stem cells (hiPSCs) have substantially improved the physiological relevance of DMD research. In this context, numerous studies have established approaches for engineering skeletal muscle tissues using rodent-derived cells [46–53]. Nevertheless, the field required more physiologically and genetically relevant systems to investigate patient-specific disease mechanisms. Human iPSCs have emerged as a powerful platform for modeling skeletal muscle disorders, including DMD [54–56]. Derived through the reprogramming of adult somatic cells into an embryonic stem cell-like state, hiPSCs possess indefinite self-renewal capacity and can differentiate into skeletal muscle cells as well as muscle stem cells (MuSCs). Importantly, they retain the genetic background of the donor, enabling faithful modeling of the diverse mutational spectrum underlying muscular dystrophies. Combining hiPSC-derived myoblast and 3D culture system it is possible to reproduce more accurately the mechanical and architectural context in which dystrophin functions. In addition, the incorporation of motor neurons can allow the study of neuromuscular junction formation and its contribution to disease progression. Collectively, animal models remain essential for investigating systemic and long-term disease manifestations, whereas advanced 3D and hiPSC-based platforms offer enhanced mechanistic resolution as also a screening tool for candidate therapeutics and direct human relevance. The integration of these approaches is therefore critical for elucidating DMD pathogenesis and accelerating the development of effective therapies. Current standard of care in duchenne muscular dystrophy Corticosteroids Corticosteroids remain the cornerstone of treatment in Duchenne muscular dystrophy [57]. The two main agents currently used are Prednisone and Deflazacort, both of which delay loss of ambulation, preserve pulmonary and cardiac function, and improve survival [58]. Their beneficial effects are linked to anti-inflammatory and immunomodulatory actions, stabilization of muscle membranes, and modulation of fibrosis and regeneration pathways. However, chronic corticosteroid therapy is associated with significant side effects, including weight gain, growth delay, osteoporosis, behavioral disturbances, cataracts, and metabolic complications. Several studies suggest that deflazacort may provide similar or slightly improved functional outcomes compared with prednisone while reducing some adverse effects, particularly excessive weight gain [59]. Vamorolone is increasingly used as a first-line corticosteroid alternative for newly diagnosed ambulatory children with DMD because it preserves the anti-inflammatory efficacy of conventional glucocorticoids while reducing long-term steroid-related complications [60]. As a dissociative glucocorticoid receptor agonist, it inhibits NF-κB signaling and stabilizes muscle membranes, providing motor benefits comparable to prednisone with fewer Cushingoid features and less impairment of growth and body mass index. However, compared with deflazacort, Vamorolone has been associated with increased behavioral and neuropsychiatric adverse effects, including mood changes, irritability, anxiety, sleep disturbances, and aggression [61]. Givinostat, a pan-histone deacetylase inhibitor, promotes muscle regeneration by enhancing myogenesis and reducing inflammation, but its clinical use is limited by adverse effects such as thrombocytopenia, myelosuppression, hypertriglyceridemia, and QTc prolongation [62]. Supportive care DMD management relies heavily on multidisciplinary supportive care, which has substantially improved survival and quality of life over recent decades. Coordinated care involves neurologists, cardiologists, pulmonologists, physiotherapists, orthopedic specialists, nutritionists, and rehabilitation teams. Early and proactive management of systemic complications is now considered essential. Progressive respiratory muscle weakness leads to restrictive lung disease, impaired cough, nocturnal hypoventilation, and recurrent infections. Standard respiratory care includes pulmonary function monitoring, assisted cough techniques, lung volume recruitment, and non-invasive ventilation when hypoventilation develops. These interventions have significantly prolonged survival in DMD patients. Cardiac involvement, particularly dilated cardiomyopathy and arrhythmias, is a major cause of mortality in DMD. Current recommendations include regular cardiac imaging and early initiation of cardioprotective therapies such as ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, often before overt systolic dysfunction appears. Physiotherapy is essential throughout disease progression to preserve mobility, prevent contractures, and maintain posture and joint flexibility. Stretching programs, orthotic support, assisted standing, and adapted rehabilitation strategies help delay musculoskeletal complications and preserve functional independence for as long as possible. Approved disease-modifying therapies Therapeutic development in DMD has undergone a major transition over the past decade, moving from purely supportive care toward mutation-targeted disease-modifying strategies. Three main therapeutic approaches have reached clinical approval or conditional approval: exon-skipping antisense oligonucleotides, nonsense mutation readthrough therapy, and AAV-mediated gene therapy (Fig. 1). Although these interventions do not fully restore dystrophin function, they represent the first clinically validated attempts to directly address the underlying molecular defect. Exon-skipping therapies Exon-skipping strategies are based on the use of antisense oligonucleotides (AONs) designed to modulate pre-mRNA splicing. By binding to specific splice sites, these molecules induce skipping of selected exons during mRNA processing, thereby restoring the translational reading frame in out-of-frame DMD mutations. The resulting truncated dystrophin protein retains essential functional domains required for sarcolemmal stability and partial muscle function preservation. Several exon-specific drugs have received regulatory approval: Eteplirsen® (exon 51 skipping), Golodirsen® (exon 53 skipping) and Casimersen® (exon 45 skipping). These therapies are applicable only to genetically defined subgroups of patients, limiting their overall population coverage. Clinical studies have demonstrated increased dystrophin expression in skeletal muscle biopsies; however, the magnitude of functional improvement remains modest and variable. A major limitation is the inefficient delivery to key tissues, particularly cardiac and smooth muscle, as well as the need for lifelong repeated intravenous administration. Nevertheless, exon skipping has established proof-of-concept that partial dystrophin restoration can modify disease biology. Beyond conventional antisense oligonucleotide-mediated exon skipping, recent advances have introduced circular ADAR-recruiting RNAs (circ-arRNAs), which leverage endogenous RNA editing machinery to achieve more durable exon skipping and sustained dystrophin expression in preclinical models and early clinical studies [63]. In a first-in-human study, a single administration of AAV-delivered circ-arRNA achieved safe, dose-dependent exon skipping in three patients, with early improvements in motor and cardiopulmonary function. The consistent restoration of dystrophin across non-human primate models, patient-derived cardiomyocytes, and treated patients, together with early functional improvements, highlights the promise of circ-arRNA-mediated exon skipping as a durable and clinically translatable therapeutic strategy [63]. Gene therapy: micro-dystrophin delivery via AAV vectors Gene replacement therapy represents one of the most advanced strategies in DMD treatment. Because the full-length dystrophin gene exceeds the packaging capacity of adeno-associated viral (AAV) vectors, engineered micro-dystrophin constructs have been developed. These truncated genes retain critical functional domains required for cytoskeletal anchoring and membrane stabilization while fitting within AAV vector constraints [64]. A leading approved therapy is Delandistrogene moxeparvovec®, which delivers a micro-dystrophin transgene systemically following a single intravenous infusion [65]. Clinical studies have demonstrated: i/ Robust micro-dystrophin expression in many, but not all, skeletal muscle biopsies, ii/ Signals of motor function stabilization or modest improvement in some patients and iii/ Feasibility of systemic gene delivery in pediatric populations. However, several important limitations remain. Immune responses to AAV capsids and transgene products can reduce efficacy and raise safety concerns. Expression durability is limited by episomal vector loss during muscle growth and regeneration. In addition, variability in transduction efficiency across muscle groups introduces heterogeneity in therapeutic response. Long-term safety and sustained functional benefit remain under active investigation [65, 66]. Finally, the doses used with conventional AAV vectors (> 1014 vector genomes per kg body weight) appear too low for widespread muscle transduction. However, newer myotropic vectors and manufacturing methods being used by Solid Biosciences and RegenexBio are beginning to overcome many of these limitations (unpublished data presented at the 2026 American Society for Gene and Cell therapy conference; abstracts published here [67]. Collectively, these approved disease-modifying therapies have established the feasibility of genetically targeted intervention in DMD. While each strategy, namely exon skipping, readthrough therapy, and gene replacement, addresses the dystrophin deficiency through distinct mechanisms, all are limited by partial efficacy, restricted patient eligibility, and challenges in systemic delivery. Nevertheless, they represent a foundational shift in DMD management, demonstrating that even partial restoration of dystrophin can modify disease progression. Ongoing improvements in vector design, oligonucleotide chemistry, and precision targeting are expected to further enhance therapeutic outcomes in the coming years. Emerging and experimental therapies Gene editing In addition to exon skipping, nonsense readthrough therapies, and AAV-mediated gene replacement strategies, CRISPR-Cas9-based genome editing has emerged as a powerful approach for the treatment of DMD, offering the potential to directly correct disease-causing mutations at their genomic source [68, 69], (Fig. 1). In contrast to gene replacement strategies, which rely on the delivery of truncated dystrophin constructs, CRISPR-mediated “myoediting” enables restoration of the endogenous DMD gene, thereby preserving physiological regulation of dystrophin expression in the appropriate tissues and at appropriate levels. These approaches have demonstrated promising results in human induced pluripotent stem cells (iPSCs) and in DMD animal models, where partial restoration of dystrophin expression has led to significant functional improvements in skeletal and cardiac muscle [69–71]. Indeed, this gene editing approach, applied to myoblasts derived from DMD patients, restored dystrophin expression in vitro, whereas transplantation of these genetically corrected cells into immunodeficient mice, induced the expression of human dystrophin in vivo. Notably, the multiplexing capability of the CRISPR/Cas9 system enables the introduction of large deletions, allowing correction of a substantial proportion of DMD mutations, potentially up to 62% [69]. Interestingly, it has been demonstrated that a single systemic administration of AAV-delivered CRISPR in mdx mice results in sustained genome editing and dystrophin restoration for up to one year [72]. However, treatment in adult mice elicits both humoral and cellular immune responses, whereas neonatal administration can mitigate immunogenicity [72]. The study also identifies unintended genomic and transcriptomic alterations associated with AAV-CRISPR editing. Despite these advances, several critical challenges must be addressed before clinical translation. First, improving editing efficiency and delivery remains a major hurdle, particularly given the need for widespread targeting of skeletal and cardiac muscle. Current delivery systems, often based on adeno-associated virus (AAV), are constrained by packaging limits and potential immunogenicity. Second, safety concerns related to off-target editing, unintended genomic alterations, and long-term effects must be rigorously evaluated. Third, robust validation in clinically relevant preclinical models, including large animals and human-derived systems, is essential to assess efficacy, durability, and safety. Fourth, suboptimal levels of gene editing can be accompanied by a loss of dystrophin expression in skeletal muscles, reflecting the relatively poor ability of conventional AAV vectors to target muscle satellite stem cells [73, 74]. Addressing these challenges will be crucial for advancing CRISPR-based therapies toward clinical application in DMD. Protein trans-splicing approaches for large dystrophin restoration Gene therapy for DMD has largely relied on micro-dystrophin (µDys) constructs compatible with AAV delivery; however, these truncated proteins lack key functional domains and provide only partial therapeutic benefit. To improve efficacy, strategies have been developed to deliver larger dystrophin variants using multiple AAV vectors. One promising approach exploits split intein-mediated protein trans-splicing, enabling the reconstitution of larger, more functional dystrophins, such as midi-dystrophin or full-length Dp427, from dual or triple AAV delivery [75, 76]. This method achieves expression levels comparable to or exceeding those of µDys without increasing vector dose and results in superior functional recovery in both skeletal and cardiac muscles in dystrophic mouse models. Despite these encouraging results, further studies are required to evaluate the long-term safety, the host immune responses toward full-length dystrophin gene therapy, and thus translational feasibility of this approach. A related approach uses dual AAV vectors to deliver N-terminal and C-terminal portions of the dystrophin cDNA. The mRNAs expressed from each carry tails that anneal with each other, enabling translational readthrough on the annealed mRNAs and production of a mini-dystrophin protein. The feasibility of this approach was presented by Insmed at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference [77, 78]. While this approach appears less efficient that split inteins, it does not require exogenous protein sequences for splicing. Insmed has also reported an approach to delivering an older AAV-µDys vector [79] via an intrathecal route, which they hope will prove less toxic to the liver. A major challenge that remains to be addressed is the development of effective alternatives to AAV vectors, which remain the predominant platform for gene therapy applications [80, 81]. The clinical utility of AAV vectors is limited by several factors, including restricted DNA carrying capacity, variable transgene persistence, and the risk of immune responses at therapeutic doses (discussed in greater detail below). Achieving efficient and widespread transduction of skeletal, diaphragmatic, and cardiac muscle, critical targets in DMD, often requires high vector doses, further increasing safety concerns and complicating clinical translation. These limitations underscore the need for alternative delivery strategies. In this context, nanoparticle-based systems represent a promising non-viral alternative for nucleic acid delivery. Nanoparticles offer several advantages, including protection of genetic cargo from degradation, tunable physicochemical properties that facilitate cellular uptake and tissue targeting, and controlled release profiles. Lipid nanoparticles (LNPs) have been extensively validated for mRNA delivery, most notably in vaccines and RNA therapeutics [82]. Recent studies have demonstrated encouraging progress for delivery of therapeutic genes. It has been demonstrated that, conversely to AAV-based delivery, LNP-mediated CRISPR editing confers enhanced resilience to repeated muscle injury, suggesting efficient targeting and modification of regenerative satellite cells [83]. These findings underscore the potential of lipid nanoparticles as a non-viral platform for achieving durable genome editing in skeletal muscle and support their development as a safer and more sustainable therapeutic strategy for DMD. Additional, emerging non-viral approaches are discussed below under “Challenges and limitations”. Cell-based therapies Another therapeutic approach that has received much attention to date is the replacement of functional dystrophin by cell transplantation interventions. Cell therapy for DMD aims to restore dystrophin expression and promote muscle repair through the transplantation of pro-myogenic cells (Fig. 1). These strategies include both allogeneic approaches, using donor-derived cells, and autologous approaches, in which patient-derived cells are genetically corrected ex vivo prior to transplantation. A variety of cell types have been explored, including myoblasts (satellite cells), mesoangioblasts, pericytes, CD133+ cells, bone marrow-derived cells, mesenchymal stem cells, and induced pluripotent stem cell (iPSC)-derived myogenic progenitors [84–86]. In preclinical models, particularly the mdx mouse, transplanted cells can engraft, differentiate, and fuse with host fibers, restoring dystrophin expression. However, clinical translation has been largely disappointing. In human trials, dystrophin restoration has been limited, often restricted to areas near injection sites, with minimal or no functional improvement. Additionally, muscle mesenchymal cells that in physiological conditions sustain or directly contribute to regeneration differentiate in adipocytes in patients with persistent damage and inflammation of the skeletal muscle [87]. Thus, several critical variables, such as identification of the mechanisms controlling myogenic potential, homing of donor populations to all musculature, avoidance of the immune response, and lack of functional improvements in clinical trial [88] are cooling the enthusiasm about stem cell therapy approach in DMD. Induced pluripotent stem cell (iPSC)-based therapy represents one of the most promising regenerative approaches for DMD, as it combines the advantages of unlimited self-renewal, patient specificity, and compatibility with genome-editing technologies. Several preclinical studies, reviewed in [89], have demonstrated that iPSC-derived myogenic progenitors can engraft into dystrophic muscle, generate dystrophin-positive myofibers, improve muscle contractile function, and, in some cases, repopulate the satellite cell niche, offering the potential for sustained muscle regeneration [90–93]. Nevertheless, the limited differentiation efficiency, cellular heterogeneity and incomplete maturation of myofibres are critical issues that limit their use. To overcome these barriers, gene overexpression approaches, typically involving myogenic regulators such as MYOD1 or PAX7, have been widely adopted, as they enable rapid and robust generation of myogenic precursors [93, 94]. However, reliance on genetic modification raises safety concerns, including insertional mutagenesis and aberrant transgene reactivation, thereby limiting their translational potential. Alternative approach that avoids the use of transgene, is based on a culture protocol that involve the combination of defined growth factor, such as bFGF and EGF, as well as GSK3 inhibition, which have been shown to generate myogenic progenitors capable of engraftment and contribution to the satellite cell pool in vivo [95, 96]. Overall, although iPSC-based therapy holds tremendous promise as a personalized regenerative treatment for DMD, further optimization of cell production, gene correction, delivery strategies, safety, and long-term efficacy is required before this approach can become a viable clinical therapy. Another potential form of cell therapy comes from efforts to enhance the function of endogenous satellite cells. As discussed, skeletal muscles in DMD boys undergo continual cycles of necrosis and regeneration, with regeneration being driven by the satellite cell pool. A long-standing dilemma in the field has been the observation that, although dystrophin is missing from the earliest stages of muscle formation, patients become stronger for several years after birth. Eventually they grow weaker and begin to lose muscle mass, and as a result it has been suggested that DMD may be primarily a disease that results from impaired regenerative potential due to senescence and/or loss of function of satellite cells, rather than the simple loss of myofiber integrity [97–100]. Rudnicki’s group reported that activated satellite cells transiently express full-length dystrophin, where it plays a critical role in establishing satellite cell polarity and promoting asymmetric cell division [101]. These findings suggest that dystrophin deficiency contributes to impaired muscle regeneration not only through myofiber instability but also by disrupting the generation of myoblasts required for efficient repair following injury. Consequently, optimal DMD therapies may need to target quiescent satellite cells in addition to myofibers and cardiomyocytes, as discussed in previous sections of this review. Alternative strategies have also been proposed, including the use of small molecules to restore asymmetric division and compensate for dystrophin deficiency, an approach that is currently progressing toward clinical evaluation [102]. However, unequivocal demonstration of dystrophin expression in satellite cells in vivo remains challenging, whereas several studies have shown that improving satellite cell function and muscle regeneration can be achieved through senolytic interventions. Therefore, it remains unclear whether satellite cell dysfunction in DMD arises predominantly from dystrophin loss, cellular senescence, or a combination of both mechanisms. Regardless of the underlying cause, accumulating evidence indicates that restoring endogenous satellite cell function represents a highly promising therapeutic strategy for DMD. Indeed, approaches aimed at correcting asymmetric cell division, reversing senescence, improving mitochondrial function, modulating key signaling pathways, including EGFR/Aurka, Notch, JAK/STAT, and Wnt, or directly restoring dystrophin expression in satellite cells have consistently enhanced muscle regeneration and functional outcomes in preclinical models [103]. Collectively, these findings highlight satellite cells as a critical therapeutic target whose functional restoration may complement current gene replacement and exon-skipping strategies, potentially leading to more durable muscle regeneration and disease modification. Utrophin upregulation as a therapeutic strategy for duchenne muscular dystrophy Utrophin (UTRN) is an autosomal paralogue of the DMD gene that has emerged as a promising therapeutic target for DMD [104–106]. The longest isoform, utrophin A, represents the muscle-specific counterpart of dystrophin and shares significant structural homology, enabling interaction with components of the dystrophin-associated protein complex (DAPC) [104, 105]. During fetal development, utrophin is broadly expressed at the sarcolemma but is largely replaced by dystrophin in adult muscle, where its localization becomes restricted to the neuromuscular and myotendinous junctions as well as regenerating fibers [107]. In dystrophic muscle, utrophin is naturally upregulated and redistributed along the sarcolemma, suggesting a compensatory role in response to the lack of dystrophin expression. This compensatory mechanism has been consistently observed in DMD patients and in animal models such as mdx mice [108–110]. It has been demonstrated that dystrophin/utrophin double knockout mice exhibit severe pathology [35, 111], whereas moderate utrophin overexpression (3–4-fold) can prevent the development of dystrophic phenotype [112, 113]. Interestingly, even modest increases (~ 1.5-fold) in utrophin expression showed functional benefits in dystrophic mouse models [113]. These findings indicate that utrophin can partially replace dystrophin function and that its expression level may influence disease severity (Fig. 1). Moreover, targeting utrophin offers several advantages over dystrophin-restoring approaches since it is well tolerated, compared to the critical immune response against dystrophin, and, most importantly, can be applied to all DMD patients, independently from the dystrophin mutations. Multiple strategies have been developed to enhance utrophin expression. Small-molecule modulators represent the most clinically advanced approach. Ezutromid (SMT C1100), identified as an activator of the utrophin A promoter [114, 115], demonstrated efficacy in preclinical models but failed to show sustained benefits in clinical trials [116, 117], likely due to metabolic instability, which has been overcome by the development of second-generation compounds with improved pharmacological properties, such as SMT022357 [118]. An alternative strategy to vehicle micro-utrophin construct was based on gene therapy approaches via adeno-associated viruses (AAVs). These constructs, designed analogously to micro-dystrophin, have shown encouraging results in preclinical models, improving muscle histopathology, function, and survival in both murine and canine models of DMD. Additional strategies include artificial transcription factors [119], CRISPR-based transcriptional activation (CRISPRa) [120], and modulation of post-transcriptional regulation. Moreover, utrophin gene expression can be modulated by microRNAs, including Let-7c, miR-150, miR-296-5p, miR-133b, and miR-196b [121]. Thus, targeting these regulators, by antisense oligonucleotides or by CRISPR-Cas9-based genome editing, resulted in transient enhancement of utrophin levels and improvement muscle [120, 122–124]. Despite these advances, utrophin is not able to completely and functionally replace dystrophin. Notably, it is unable to anchor neuronal nitric oxide synthase (nNOS) at the sarcolemma [125] and does not fully restore microtubule organization in dystrophic fibers [126]. These limitations suggest that while utrophin upregulation is a highly promising and broadly applicable therapeutic strategy, it may need to be combined with complementary approaches to achieve optimal clinical benefit. Anti-fibrotic and anti-inflammatory approaches One of the pathologic consequences of the lack of dystrophin is the sarcolemmal instability, which induces excessive calcium (Ca2+) influx, leading to myofiber necrosis and the progressive replacement of muscle tissue with fibrotic and adipose tissue. Continuous cycles of muscle fiber damage and regeneration trigger a chronic inflammatory response. Necrotic fibers are infiltrated by immune cells, particularly macrophages, both M1 and M2, which dominate the inflammatory niche, along with the infiltration of CD4+ T lymphocytes (with fewer CD8+ T cells), B cells, and dendritic cells. The establishment of chronic inflammation leads to fibrosis that further exacerbates the disease. Currently, glucocorticoids represent the standard treatment for DMD due to their potent anti-inflammatory and immunosuppressive effects. However, long-term glucocorticoids treatment is associated with significant adverse effects, including muscle atrophy due to protein catabolism, weight gain/obesity, growth suppression, cushingoid features, delayed puberty, osteoporosis/fractures, and cataracts. Thus, their overall benefit reflects a balance between reducing inflammation and promoting muscle wasting. Among inflammatory cytokines, elevated levels of the inflammatory cytokine IL-6 have been detected in the serum of both boys with DMD and mdx mouse model, as well as in inflammatory cells infiltrating their muscle tissue [127]. Notably, IL-6 levels are higher in untreated patients compared to those receiving glucocorticoid therapy, suggesting a link between IL-6 and disease activity [127]. Together, these findings indicate that IL-6 may contribute to muscle damage by promoting inflammation. To investigate this, mdx mice were treated with an antibody targeting the IL-6 receptor. Compared to untreated controls, treated mice exhibited reduced myofiber necrosis, improved exercise performance, and a diminished inflammatory response in muscle tissue, supporting a pathogenic role for IL-6 in dystrophic progression. A deeper understanding of the interplay between immune cells, cytokines, and muscle pathology in DMD is essential for developing targeted therapies that minimize side effects while preserving or enhancing muscle regeneration. Metabolic and mitochondrial therapies Mitochondrial dysfunction and impaired energy metabolism are critical contributors to disease progression. Mitochondrial abnormalities in DMD include disrupted calcium homeostasis, excessive production of reactive oxygen species (ROS), and altered mitochondrial dynamics, all of which contribute to muscle degeneration, inflammation, and fibrosis. It has been demonstrated that the mitochondrial-targeted peptide E.M.P-2, which chelates calcium and counteract mitochondrial ROS production, is also able to suppresses inflammation by inhibiting IL-6 and TGF-β expression [128], suggesting that correcting mitochondrial dynamics can broadly ameliorate dystrophic pathology. In addition, modulation of pathways that govern cellular energy-balance represents another promising therapeutic approach. Sustained activation of AMP-activated protein kinase (AMPK), a key regulator of cellular metabolism, has been shown to improve muscle function and metabolic health in dystrophic models [129]. Importantly, such approaches, by improving mitochondrial function and enhancing the metabolic signaling (Fig. 1), are mutation-independent, since can be applied to all DMD patients, and may provide safer alternatives or complementary strategies to other current therapies. Challenges and limitations Mutation-specific therapies As with other X-linked, recessive lethal genetic disorders, DMD is a new mutation syndrome and one-third of all cases arise from a spontaneous, new mutation [130]. Combined with the enormous size of the locus (> 2.2 MB) a result is that thousands of independent mutations have been identified that present significant challenges for prenatal diagnosis, carrier testing and precision medicine approaches targeted at specific mutations [131]. While gene replacement and metabolic/pathway modulating strategies can be universally applied to most DMD-causing mutations, their overall efficacy remains somewhat suboptimal, as noted above. However, it remains unclear whether this is true for Becker muscular dystrophy (BMD) mutations, where some dystrophin, often carrying internal deletions, is produced in muscles. For example, overexpression of microdystrophin or C-terminal dystrophin isoforms can sometimes displace endogenous dystrophin or utrophin, potentially exacerbating the phenotype, especially with suboptimal micro-dystrophins. However, this has only been observed when the exogenous dystrophin is expressed at enormous levels, typically > 10X normal dystrophin expression [132–135], and in rare cases of DMD [136, 137]. A recent case of a patient dying more than a year after receiving Pfizer’s AAV-µDys vector revealed that the individual expressed a BMD-like dystrophin, even though he presented with a typical DMD phenotype. While no evidence has been gathered suggesting that the fatality was due to an interaction between µDys and the BMD-like endogenous dystrophin, the case has raised some questions about the safety of gene replacement in BMD patients. An alternative approach in these and other cases would be methods that target specific mutations to enable expression of larger, or even full-length dystrophins. CRISPR-based strategies outlined above are one potential method to achieve this goal, but universal application of CRISPR approaches could ultimately require the design of dozens, if not hundreds, of different therapeutic drugs to target mutations in any of the 79 exons that encode the muscle isoform of dystrophin. Several alternative strategies have been suggested to simplify this approach (Fig. 1). One is the development of a ‘cut and paste’ method whereby a portion of the dystrophin cDNA could be inserted into one of the 2 deletion ‘hot-spots’ in the dystrophin gene. This approach could lead to a vector or drug that could be used on a high percentage of deletions that span relatively large regions of the DMD gene [70, 138]. Another approach is to use vectors that enable RNA splicing onto a mutant transcript to replace the mutant part of the mRNA. In theory, one 5’- dystrophin RNA vector or one 3’ dystrophin RNA splicing vector could be adapted to target most mutations [139]. However, neither of these approaches is yet sufficiently efficient to warrant clinical trials. Delivery efficiency and serious adverse events A major rate limiting step for all nucleic acid-based therapies remains the efficiency of gene delivery to muscles bodywide. The discovery that high-dose vascular infusion of AAV vectors can be used for systemic gene delivery to muscles [140] has led to nearly 10,000 neuromuscular disease patients being treated [141]. However, doses used for efficient dystrophin replacement or gene editing in animal models (> 1014 vector genomes per kg body mass) are less efficient in patients and, in the case of Elevidys, typically result in dystrophin levels 30% or lower as assayed by western blot and by immunostaining [65, 142]. This inefficiency is one of the major factors limiting efficacy of AAV-based therapies. While higher vector doses could potentially overcome these limitations, current doses are already at the upper limit of safety and have led to several serious adverse events (SAEs) and several fatalities [143]. The development of myotropic AAV capsids can potentially increase safety and efficiency of gene delivery by allowing systemic delivery at significantly lower doses. For example, the labs of D. Grimm and P Sabeti both described modified AAV capsids incorporating ligands for integrin receptors (all carry an ‘RGD’ amino acid motif), enabling systemic delivery at doses at least 10-fold lower than conventional AAVs such as AAV8 or AAV9 [144–146]. Whether the hoped for lower doses will work in patients remains somewhat unclear. Novartis has announced that they will soon begin a clinical trial to deliver an older AAV-µDys vector, but with their newest myotropic capsid designed by Kate Therapeutics [147]. To date only one myotropic AAV has reached the clinic, and this newer “Polaris” AAV developed by Solid Biosciences has led to the highest dystrophin levels seen to date in clinical trials, although their dose remains at 1014 vector genomes per kg (presentation at 2026 ASGCT Conference, see abstracts [67]). Genethon has also recently developed an alternative RGD vector that displays enhanced myotropism across multiple species [148]. Developing AAVs with improved delivery efficiency is a major focus of study by many labs and biotech companies, and if vectors can be found that allow efficient delivery at doses in the 1013 vector genomes per kg range it is expected that many current serious adverse events (SAEs) due to high vector dose may be avoided [81, 141]. An alternative to myotropic AAVs is the use of myotropic lentiviral vectors (Lv). Unlike AAV, Lv efficiently integrate within the host cell genome and have potential for long-term gene expression, even in dividing cells. Conventional lentiviral vectors pseudotyped with the VSV-G envelope glycoprotein have previously been shown to be poor transducers of myofibers and not amenable to systemic delivery [149]. However, modified Lvs pseudotyped with mammalian myogenic cell fusogens was shown to be able to target activated satellite cells body wide following intravascular infusion [150]. Further, this vector system did not appear to be immunogenic and could be administered multiple times, allowing for additional increases in transduction. The Lv system can carry expression cassettes up to ~ 8 kb in size, such that larger mini-dystrophins can be delivered. An alternative is the use of non-viral delivery systems such as lipid nanoparticles (LNPs) or ligand-conjugated nucleic acids. While such strategies have been touted as being the future of gene therapy for decades, their overall efficiency remains lower than obtained with AAV. Nonetheless, this picture may be starting to change, although whether any such approaches will ever become a useful and approved therapeutic will likely require many years of testing and refinement. Several groups (Avidity Biosciences [151]; and Dyne Therapeutics [152]) have begun using miniaturized transferrin-receptor antibody conjugated anti-sense oligonucleotides (ASO) to enhance exon-skipping strategies, and one group (Myosana [153]) has conjugated a GLUT4 antibody directly onto dystrophin cDNAs. Both approaches are leading to dystrophin expression levels in the 5–25% range, depending on the conditions [67, 77, 154]. While ASO delivery is limited to individual exons, cDNA delivery could be applied for most mutations. Similar approaches are under development with LNP-type vehicles, although these appear even further away from therapeutic relevance than the approaches in the previous paragraph. These methods use ligand-incorporation into the LNPs, or modified lipid designs to enhance muscle uptake. While several companies have presented promising, albeit unpublished, data, most notably at the above-referenced MDA conference, little, if any, of these findings has been peer reviewed. One exception was a recent report from Spot Bio, a Chinese company, that used extracellular vesicles (EVs) to deliver full-length dystrophin mRNA to skeletal muscles, although the EVs apparently do not target cardiac muscle [155]. This approach used EVs loaded with “muscle-targeting peptides” that enhanced skeletal muscle targeting. The best peptides all contained an RGD motif similar to those in myotropic AAVs that target various integrin receptors. Of note, the mice received continuous immune suppression throughout the study. While this method led to high levels of dystrophin in mdx mice, the company recently announced that they have treated 2 DMD patients with a similar approach but one that delivers a dystrophin cDNA, rather than mRNA. No results from the trial have been released [156]. Entos Pharmaceuticals reported at the 2026 MDA conference that they have developed lipid nanoparticle-like delivery vehicles that incorporate fusogenic transmembrane proteins on their surface, which they say enhances targeting to muscle and other organs. These PLV particles have been used for dystrophin delivery bodywide to mdx mice [157]. Finally, SonoThera [158] has developed a unique delivery system that uses no vector or LNP system. Their approach delivers plasmid DNA, such as a full-length dystrophin expression cassette, intravascularly together with microbubbles, followed by focused ultrasound, which has led to widespread uptake into muscles bodywide in mice and non-human primates. Long-term safety and durability These various approaches discussed above are all designed to develop long-term and safe approaches to achieving genetic therapies for Duchenne and other muscular dystrophies (Fig. 1). As discussed, AAV remains the most efficient known method for systemic gene delivery to muscle, but AAV trials continue to be associated with rare, but serious adverse events (SAEs). While the newer, myotropic vectors discussed above may reduce or eliminate many such SAEs against the vector, the overall safety of these approaches will undoubtedly benefit from further improvements that can lower dose. The primary reason for continuing interest in AAV technologies remains their potential for “one and done” therapies. AAV vectors have been shown to be stably expressed for at least 5 years in DMD clinical trials, and more than double this time in animal models. While the non-viral approaches discussed above may be an alternative way to overcome AAV toxicity, all these methods will require repeat dosing, potentially as often as every few months for the lifetime of a patient. Long-term safety of such repeat dosing remains to be determined. One exception to these considerations might be successful and efficient implementation of gene editing technologies, especially as they can be targeted to muscle satellite cells, which is required to enable longer-term expression than is obtained by current methods that only target mature striated muscles. Perhaps a more concerning long-term issue aside from delivery vehicle toxicity is the problem of immune responses to dystrophin. Since DMD is a genetic null-allele disorder, and BMD patients typically only express portions of the endogenous dystrophin gene, any method that enables dystrophin expression has the potential to elicit a cellular immune response against the newly produced dystrophin. Such immune responses have already been seen in several AAV-µDys targeted patients, and in some cases appear to have resulted in a complete loss of expression [159]. While most if not all such events have been observed in AAV trials, as the alternative methods begin to be tested in the clinic it will be important to also monitor potential dystrophin immune responses in those studies. Immunity is modulated at least in part via the promoter/enhancer elements used in the vectors, and muscle-restricted promoters have been shown to reduce, although not eliminate T-cell immune response to transgenes [160]. One approach to further dampen immunity could be by inducing tolerance, and some reports suggest that liver expression could be one way to achieve these after AAV delivery [161, 162]. An alternative approach, as discussed above, is to deliver a surrogate gene, such as utrophin, which should not be immunogenic in DMD boys [163, 164]. Several groups are moving towards clinical trials of utrophin vectors, so it will be interesting to observe their relative potency and immunogenicity compared with dystrophin-centric approaches. Cost and accessibility Along with increasing treatment options comes increasing costs, and in many cases limited accessibility (Fig. 1). AAV technologies have the potential to last for 10 years or perhaps far longer, such that they are often claimed to be a one and done therapy, and perhaps as a result their costs are astronomical. For example, Sarepta charges $3.2 million dollars per dose of Elevidys, and AAV therapies for other disorders are also enormously expensive. With the likelihood of a growing number of alternative AAV-µDys therapies obtaining approval in the next year, it is unclear if costs will come down due to competition, or if these other companies will charge similarly high amounts. Much of this cost reflects recouping years of research and developmental costs, even though much of the groundbreaking original research was originally paid for by taxpayers through NIH and other grant providers. An additional factor contributing to these enormous costs is the difficulty in producing AAV vectors at scale in a reproducible manner that allows for ensuring consistent quality control potency. As manufacturing technologies continue to improve and are scaled up to meet demand, perhaps costs will come down, but that remains to be seen. Unfortunately, alternative, non-viral therapies such as exon skipping are not much cheaper. While a typical dose of a non-viral anti-sense oligonucleotide treatment is in the range of several hundred thousand dollars per dose, these and other non-viral delivery systems must be administered several times a year throughout a patient’s lifetime. In the United States, much of these costs are covered by insurance companies, assuming one has insurance, but how this will change in the future and how it impacts patient care in other countries is problematic. Many emerging therapeutics carry enough risk that patients often need to be treated at specialty clinics and remain close to the clinic for a month or two after drug infusion, such that accessibility is difficult if not impossible outside of cities with major medical centers. While we are witnesses an amazing increase in molecular technologies capable of treating numerous neuromuscular disorders, cost and accessibility issues are not keeping up with demand. Future perspectives Combination therapies Emerging evidence increasingly supports the concept that single-agent approaches are unlikely to fully address the complex multisystem pathology of DMD. Future therapeutic strategies are therefore expected to move toward rationally designed combination therapies that target complementary disease mechanisms (Fig. 1). These may include approaches aimed at restoring dystrophin expression alongside interventions that reduce fibrosis, modulate chronic inflammation, and enhance muscle regeneration. Such multimodal strategies are anticipated to provide synergistic benefits and improve both skeletal and cardiac muscle outcomes. Personalized medicine approaches The genetic and clinical heterogeneity of DMD highlights the need for more individualized therapeutic strategies. Personalized medicine approaches are expected to integrate genetic mutation class, disease stage, biomarker signatures, and functional assessments to guide treatment selection and timing (Fig. 1). This stratification will be essential not only for optimizing patient benefit in clinical practice but also for improving the design and interpretation of clinical trials through more homogeneous and well-defined patient cohorts. Biomarkers and outcome measures Robust biomarkers and sensitive outcome measures are essential for accelerating translational progress in DMD. Current efforts focus on refining circulating biomarkers, imaging-based readouts, and functional assessments that more accurately reflect disease activity and therapeutic response (Fig. 1). The integration of multi-omics profiling, digital health technologies, and longitudinal data collection is expected to enhance patient stratification and provide more precise, quantitative endpoints. These advances will be critical for reducing variability in clinical trials and improving the evaluation of emerging therapeutic strategies. Conclusion Duchenne muscular dystrophy is an inherited neuromuscular disorder which still lacks resolutive therapeutic approaches. Several therapeutic strategies have been developed; exon-skipping therapies, nonsense mutation readthrough agents, and AAV-mediated micro-dystrophin gene replacement have provided proof that partial restoration of dystrophin protein can modify disease progression (Fig. 1). Nevertheless, several critical challenges remain to be addressed. Interestingly, the emerging approaches, including CRISPR/Cas9 genome editing, improved gene delivery systems, utrophin upregulation, cell-based therapies, and metabolic, anti-inflammatory, and anti-fibrotic interventions, offer promising avenues to overcome the limitations of current treatments (Fig. 1). Continued advances in gene editing, vector engineering, non-viral delivery platforms, biomarker discovery, and personalized medicine are expected to further improve therapeutic efficacy and patient outcomes (Fig. 1). Ultimately, translating these innovations into safe, durable, and accessible treatments will require close collaboration between researchers, clinicians, regulatory agencies, industry, and patient communities to efficiently improve both the quality of life and long-term prognosis of patients with DMD (Fig. 1).